Expression of CXCL1 in human endothelial cells induces angiogenesis through the CXCR2 receptor and the ERK1/2 and EGF pathways

Laboratory Investigation

Volumn 93, Issue 7, 2013, Pages 768-778

  Miyake, Makito ^a   Goodison, Steve ^a,b   Urquidi, Virginia ^a   Gomes Giacoia, Evan ^a   Rosser, Charles J ^a,b  

^a M D ANDERSON CANCER CENTER ORLANDO   (United States)

^b Nonagen Bioscience Corp   (United States)

Author keywords

angiogenesis; chemokine (C X C motif) ligand 1; endothelial cell; epidermal growth factor

Indexed keywords

CHEMOKINE RECEPTOR CXCR2; CXCL1 CHEMOKINE; CYCLIN D; CYCLIN DEPENDENT KINASE 4; CYCLIN DEPENDENT KINASE INHIBITOR 1; EPIDERMAL GROWTH FACTOR; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3;

ANGIOGENESIS; ANTIANGIOGENIC ACTIVITY; ARTICLE; CAPILLARY TUBE; CELL CYCLE; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CELL MIGRATION; CELL PROLIFERATION; CELL VIABILITY; CONTROLLED STUDY; CYTOKINE RELEASE; ENDOTHELIUM CELL; HUMAN; HUMAN CELL; IN VITRO STUDY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; WOUND HEALING;

ANIMALS; CELL CYCLE CHECKPOINTS; CELL MOVEMENT; CHEMOKINE CXCL1; ENDOTHELIAL CELLS; EPIDERMAL GROWTH FACTOR; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; HUMANS; MALE; MAP KINASE SIGNALING SYSTEM; MICE; MICE, INBRED BALB C; MICE, NUDE; NEOVASCULARIZATION, PATHOLOGIC; RECEPTORS, INTERLEUKIN-8B;

EID: 84879668186     PISSN: 00236837     EISSN: 15300307     Source Type: Journal    
DOI: 10.1038/labinvest.2013.71     Document Type: Article

References (48)

1. Folkman J. Angiogenesis in cancer, vascular, rheumatoid, and other diseases. Nat Med 1985;1:27-31.
2. Folkman J, Klagsbrun M. Angiogenic factors. Science 1987;235: 442-447. (Pubitemid 17009577)
3. Hanahan D, Folkman J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 1996;86:353-364. (Pubitemid 26272076)
4. Liotta LA, Kleinerman J, Saidel GM. Quantitative relationships of intravascular tumor cells, tumor vessels, and pulmonary metastases following tumor implantation. Cancer Res 1974;34:997-1003.
5. Weidner N, Folkman J, Pozza F, et al. Tumor angiogenesis: a new significant and independent prognostic indicator in early stage breast carcinoma. J Natl Cancer Inst 1992;84:1875-1887. (Pubitemid 23004615)
6. Bochner BH, Cote RJ, Weidner N. Angiogenesis in bladder cancer: relationship between microvessel density and tumor prognosis. J Natl Cancer Inst 1995;87:1603-1612.
7. Klagsbrun M, D'Amore PA. Regulators of angiogenesis. Ann Rev Physiol 1991;53:217-239.
8. Liotta LA, Steeg PS, Stetler-Stevenson WG. Cancer metastasis and angiogenesis: an imbalance of positive and negative regulation. Cell 1991;64:327-336. (Pubitemid 121001258)
9. Blood CH, Zetter BR. Tumor interactions with the vasculature: angiogenesis and tumor metastasis. Biochem Biophys Acta 1990;1032:89-118.
10. Grossfeld GD, Ginsberg DA, Stein JP. Thrombospondin-1 expression in bladder cancer: association with p53 alterations, tumor angiogenesis, and tumor progression. J Natl Cancer Inst (Bethesda, MD) 1997;89:219-227. (Pubitemid 27073759)
11. Folkman J, Ingber D. Inhibition of angiogenesis. Semin Cancer Biol 1992;3:89-96.
12. Sidky YA, Borden EC. Inhibition of angiogenesis by interferons: effects on tumor-and lymphocyte-induced vascular responses. Cancer Res 1987;47:5155-5161. (Pubitemid 17146488)
13. O'Brien T, Cranston D, Fuggle S, et al. Two mechanisms of basic fibroblast growth factor-induced angiogenesis in bladder cancer 1997). Cancer Res, 57:136-140.
14. Kö llermann J, Helpap B. Expression of vascular endothelial growth factor (VEGF) and VEGFreceptor Flk-1 in benign, premalignant, and malignant prostate tissue. Am J Clin Pathol 2001;116:115-121. (Pubitemid 32601135)
15. Ferrara N, Davis-Smyth T. The biology of vascular endothelial growth factor. Endocr Rev 1997;18:4-25. (Pubitemid 27076453)
16. Inoue K, Slaton JW, Eve BY, et al. Interleukin 8 expression regulates tumorigenicity and metastases in androgen-independent prostate cancer. Clin Cancer Res 2000;6:2104-2119. (Pubitemid 30305111)
17. Uehara H, Troncoso P, Johnston D, et al. Expression of interleukin-8 gene in radical prostatectomy specimens is associated with advanced pathologic stage. Prostate 2005;64:40-49. (Pubitemid 40734737)
18. O'Brien TS, Fox SB, Dickenson AJ, et al. Expression of the angiogenic factor thymidine phosphorylase/platelet-derived endothelial cell growth factor in primary bladder cancers. Cancer Res 1996;56: 4799-4804. (Pubitemid 26338087)
19. Miyake H, Hoshimura K, Hara I, et al. Basic fibroblast growth factor regulates matrix metalloproteinases production and in vitro invasiveness in human bladder cancer cell lines. J Urol 1997;157: 2351-2355. (Pubitemid 27208720)
20. Sakai Y, Goodison S, Kusmartsev S, et al. Bcl-2 mediated modulation of vascularization in prostate cancer xenografts. Prostate 2009;69: 459-470.
21. Sakai Y, Goodison S, Cao W, et al. VEGF induces expression of Bcl-2 and multiple signaling factors in microvascular endothelial cells in a prostate cancer model. World J Urol 2009;27:659-666.
22. Raghuwanshi SK, Su Y, Singh V, et al. The chemokine receptors CXCR1 and CXCR2 couple to distinct g protein-coupled receptor kinases to mediate and regulate leukocyte functions. J Immunol 2012;189: 2824-2832.
23. Su Y, Raghuwanshi SK, Yu Y, et al. Altered CXCR2 signaling in betaarrestin-2-deficient mouse models. J Immunol 2005;175:5396-5402. (Pubitemid 41456426)
24. Anai S, Sakamoto N, Sakai Y, et al. Dual targeting of Bcl-2 and VEGF: a potential strategy to improve therapy for prostate cancer. Urol Oncol 2011;29:421-429.
25. Park MJ, Kwak HJ, Lee HC, et al. Nerve growth factor induces endothelial cell invasion and cord formation by promoting matrix metalloproteinase-2 expression through the phosphatidylinositol 3-kinase/Akt signaling pathway and AP-2 transcription factor. J Biol Chem 2007;282:30485-30496.
26. Maeshima Y, Colorado PC, Torre A, et al. Distinct antitumor properties of a type IV collagen domain derived from basement membrane. J Biol Chem 2000;275:21340-21348. (Pubitemid 30481833)
27. Bonfil RD, Vinyals A, Bustuoabad OD, et al. Stimulation of angiogenesis as an explanation of Matrigel-enhanced tumorigenicity. Int J Cancer 1994;58:233-239. (Pubitemid 24240101)
28. Prewett M, Huber J, Li Y, et al. Antivascular endothelial growth factor receptor (fetal liver kinase 1) monoclonal antibody inhibits tumor angiogenesis and growth of several mouse and human tumors. Cancer Res 1999;59:5209-5218. (Pubitemid 29503984)
29. Pang X, Yi Z, Zhang X, et al. Acetyl-11-keto-beta-boswellic acid inhibits prostate tumor growth by suppressing vascular endothelial growth factor receptor 2-mediated angiogenesis. Cancer Res 2009;69: 5893-5900.
30. De-Chao Yu Jun g-Sun Lee, Yoo JiYoung, Shin Hyewon, et al. Soluble vascular endothelial growth factor decoy receptor FP3 exerts potent antiangiogenic effects. Mol Ther 2012;20:938-947.
31. Fuhler GM, Knol GJ, Drayer AL, et al. Impaired interleukin-8-and GROalpha-induced phosphorylation of extracellular signal-regulated kinase result in decreased migration of neutrophils from patients with myelodysplasia. J Leukoc Biol 2005;77:257-266. (Pubitemid 40326224)
32. Moll NM, Cossoy MB, Fisher E, et al. Imaging correlates of leukocyte accumulation and CXCR4/CXCL12 in multiple sclerosis. Arch Neurol 2009;66:44-53.
33. Gillitzer R, Goebeler M. Chemokines in cutaneous wound healing. J Leukoc Biol 2001;69:513-521. (Pubitemid 32294835)
34. Hembruff SL, Cheng N. Chemokine signaling in cancer: Implications on the tumor microenvironment and therapeutic targeting. CancerTher 2009;7:254-267.
35. Zhong L, Roybal J, Chaerkady R, et al. Identification of secreted proteins that mediate cell-cell interactions in an in vitro model of the lung cancer microenvironment. Cancer Res 2008;68:7237-7245.
36. Wang D, Wang H, Brown J, et al. CXCL1 induced by prostaglandin E2 promotes angiogenesis in colorectal cancer. J Exp Med 2006;203: 941-951.
37. Baird AM, Gray SG, O'Byrne KJ. Epigenetics underpinning the regulation of the CXC (ELR\+) chemokines in non-small cell lung cancer. PLoS One 2011;6:e14593.
38. Warner KA, Miyazawa M, Cordeiro MM, et al. Endothelial cells enhance tumor cell invasion through a crosstalk mediated by CXC chemokine signaling. Neoplasia 2008;10:131-139. (Pubitemid 351240879)
39. Wang D, Richmond A. Nuclear factor-kappa B activation by the CXC chemokine melanoma growth-stimulatory activity/growth-regulated protein involves the MEKK1/p38 mitogen-activated protein kinase pathway. J Biol Chem 2001;276:3650-3659.
40. Wang B, Hendricks DT, Wamunyokoli F, et al. A growth-related oncogene/CXC chemokine receptor 2 autocrine loop contributesto cellular proliferation in esophageal cancer. Cancer Res 2006;66: 3071-3077.
41. Matsushima K, Morishita K, Yoshimura T, et al. Molecular cloning of a human monocyte-derived neutrophil chemotactic factor (MDNCF) and the induction of MDNCF mRNA by interleukin-1 and tumor necrosis factor. J Exp Med 1988;167:883-18793.
42. Matsushima K, Baldwin ET, Mukaida N. Interleukin-8 and MDAF: novel leukocyte recruitment and activity cytokines. Chem Immunol 1992;51:236-265.
43. Koch AE, Polverini PS, Kunkel SL, et al. Interleukin-8 as a macrophagederived mediator of angiogenesis. Science 1992;258:1798-1801.
44. Strieter RM, Kunkel SL, Elner VM, et al. Interleukin-8: a corneal factor that induces neovascularization. Am J Pathol 1992;141: 1270-1284.
45. Wang JM, Taraboletti G, Matsushima K, et al. Induction of hepatotactic migration of melanoma cells by neutrophil activating protein/IL-8. Biochem Biophys Res Commun 1990;169:165-170. (Pubitemid 20181008)
46. Schandendorf D, Moller A, Algermissen B, et al. IL-8 produced by human malignant melanoma cells in vitro is an essential autocrine growth factor. J Immunol 1993;151:2667-2675. (Pubitemid 23264518)
47. Krueger G, Jorgensen C, Miller C, et al. Effect of IL-8 on epidermal proliferation. J Invest Dermatol 1990;94:545.
48. Kaneko T, Zhang Z, Mantellini MG, et al. Bcl-2 orchestrates a cross-talk between endothelial and tumor cells that promotes tumor growth. Cancer Res 2007;67:9685-9693. (Pubitemid 47621215)